Cytokine production in the bone marrow microenvironment: Failure to demonstrate estrogen regulation in early postmenopausal women

Moustapha Kassem, Sundeep Khosla, Thomas C. Spelsberg, B. Lawrence Riggs

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Recent studies in rodents and in human in vitro systems suggest that the action of estrogen on bone is modulated by various bone-resorbing cytokines produced by osteoblasts, bone marrow cells, or both, but results among studies have been conflicting. Thus, we studied 20 untreated women (controls/and 20 women who had received estrogen replacement therapy since the time of menopause; both groups were 5 ± 1 yr (mean ± SE) postmenopausal. From bone marrow aspirates, we obtained marrow plasma to evaluate the production of cytokines by marrow and trabecular bone cells in vivo and marrow mononuclear cells to assess in vitro the constitutive and lipopolysaccharide-stimulated production of cytokines and also to test the in vitro effects of 17β-estradiol (10-8 mol/L). Interleukin-1α (IL-1α), IL- 1β, IL-6, IL-1 receptor antagonist, and IL-6-soluble receptor were measured by specific enzyme-linked immunosorbent assay. No statistically significant difference between the two groups in the level of any of these cytokines was detected in the bone marrow plasma or the conditioned medium in vitro. Furthermore, in vitro treatment with 17β-estradiol did not affect basal or lipopolysaccharide-stimulated cytokine production. Thus, our data suggest that for normal postmenopausal women, mediation of the effects of estrogen by a single cytokine is unlikely. Either multiple cytokines are involved and small changes in these are difficult to detect in clinical investigative studies, or other mechanisms are operative.

Original languageEnglish (US)
Pages (from-to)513-518
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume81
Issue number2
DOIs
StatePublished - 1996

Fingerprint

Bone
Estrogens
Bone Marrow
Cytokines
Interleukin-1
Lipopolysaccharides
Estradiol
Interleukin-6
Plasmas
Interleukin-6 Receptors
Bone and Bones
Immunosorbents
Estrogen Replacement Therapy
Interleukin-1 Receptors
Osteoblasts
Conditioned Culture Medium
Menopause
Bone Marrow Cells
Rodentia
Assays

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Cytokine production in the bone marrow microenvironment : Failure to demonstrate estrogen regulation in early postmenopausal women. / Kassem, Moustapha; Khosla, Sundeep; Spelsberg, Thomas C.; Riggs, B. Lawrence.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 81, No. 2, 1996, p. 513-518.

Research output: Contribution to journalArticle

@article{bc12d7c66ad94e0a86ab596b648df31b,
title = "Cytokine production in the bone marrow microenvironment: Failure to demonstrate estrogen regulation in early postmenopausal women",
abstract = "Recent studies in rodents and in human in vitro systems suggest that the action of estrogen on bone is modulated by various bone-resorbing cytokines produced by osteoblasts, bone marrow cells, or both, but results among studies have been conflicting. Thus, we studied 20 untreated women (controls/and 20 women who had received estrogen replacement therapy since the time of menopause; both groups were 5 ± 1 yr (mean ± SE) postmenopausal. From bone marrow aspirates, we obtained marrow plasma to evaluate the production of cytokines by marrow and trabecular bone cells in vivo and marrow mononuclear cells to assess in vitro the constitutive and lipopolysaccharide-stimulated production of cytokines and also to test the in vitro effects of 17β-estradiol (10-8 mol/L). Interleukin-1α (IL-1α), IL- 1β, IL-6, IL-1 receptor antagonist, and IL-6-soluble receptor were measured by specific enzyme-linked immunosorbent assay. No statistically significant difference between the two groups in the level of any of these cytokines was detected in the bone marrow plasma or the conditioned medium in vitro. Furthermore, in vitro treatment with 17β-estradiol did not affect basal or lipopolysaccharide-stimulated cytokine production. Thus, our data suggest that for normal postmenopausal women, mediation of the effects of estrogen by a single cytokine is unlikely. Either multiple cytokines are involved and small changes in these are difficult to detect in clinical investigative studies, or other mechanisms are operative.",
author = "Moustapha Kassem and Sundeep Khosla and Spelsberg, {Thomas C.} and Riggs, {B. Lawrence}",
year = "1996",
doi = "10.1210/jc.81.2.513",
language = "English (US)",
volume = "81",
pages = "513--518",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Cytokine production in the bone marrow microenvironment

T2 - Failure to demonstrate estrogen regulation in early postmenopausal women

AU - Kassem, Moustapha

AU - Khosla, Sundeep

AU - Spelsberg, Thomas C.

AU - Riggs, B. Lawrence

PY - 1996

Y1 - 1996

N2 - Recent studies in rodents and in human in vitro systems suggest that the action of estrogen on bone is modulated by various bone-resorbing cytokines produced by osteoblasts, bone marrow cells, or both, but results among studies have been conflicting. Thus, we studied 20 untreated women (controls/and 20 women who had received estrogen replacement therapy since the time of menopause; both groups were 5 ± 1 yr (mean ± SE) postmenopausal. From bone marrow aspirates, we obtained marrow plasma to evaluate the production of cytokines by marrow and trabecular bone cells in vivo and marrow mononuclear cells to assess in vitro the constitutive and lipopolysaccharide-stimulated production of cytokines and also to test the in vitro effects of 17β-estradiol (10-8 mol/L). Interleukin-1α (IL-1α), IL- 1β, IL-6, IL-1 receptor antagonist, and IL-6-soluble receptor were measured by specific enzyme-linked immunosorbent assay. No statistically significant difference between the two groups in the level of any of these cytokines was detected in the bone marrow plasma or the conditioned medium in vitro. Furthermore, in vitro treatment with 17β-estradiol did not affect basal or lipopolysaccharide-stimulated cytokine production. Thus, our data suggest that for normal postmenopausal women, mediation of the effects of estrogen by a single cytokine is unlikely. Either multiple cytokines are involved and small changes in these are difficult to detect in clinical investigative studies, or other mechanisms are operative.

AB - Recent studies in rodents and in human in vitro systems suggest that the action of estrogen on bone is modulated by various bone-resorbing cytokines produced by osteoblasts, bone marrow cells, or both, but results among studies have been conflicting. Thus, we studied 20 untreated women (controls/and 20 women who had received estrogen replacement therapy since the time of menopause; both groups were 5 ± 1 yr (mean ± SE) postmenopausal. From bone marrow aspirates, we obtained marrow plasma to evaluate the production of cytokines by marrow and trabecular bone cells in vivo and marrow mononuclear cells to assess in vitro the constitutive and lipopolysaccharide-stimulated production of cytokines and also to test the in vitro effects of 17β-estradiol (10-8 mol/L). Interleukin-1α (IL-1α), IL- 1β, IL-6, IL-1 receptor antagonist, and IL-6-soluble receptor were measured by specific enzyme-linked immunosorbent assay. No statistically significant difference between the two groups in the level of any of these cytokines was detected in the bone marrow plasma or the conditioned medium in vitro. Furthermore, in vitro treatment with 17β-estradiol did not affect basal or lipopolysaccharide-stimulated cytokine production. Thus, our data suggest that for normal postmenopausal women, mediation of the effects of estrogen by a single cytokine is unlikely. Either multiple cytokines are involved and small changes in these are difficult to detect in clinical investigative studies, or other mechanisms are operative.

UR - http://www.scopus.com/inward/record.url?scp=0030064975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030064975&partnerID=8YFLogxK

U2 - 10.1210/jc.81.2.513

DO - 10.1210/jc.81.2.513

M3 - Article

C2 - 8636260

AN - SCOPUS:0030064975

VL - 81

SP - 513

EP - 518

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -